BioNTech Gross Profit from 2010 to 2024

BNTX Stock

USD 113.13 4.90 4.53%

BioNTech Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit BioNTech SE makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2018-06-30

Previous Quarter

68.9 M

Current Value

1.1 B

Quarterly Volatility

1.7 B

Covid

Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.

Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of BioNTech SE over the last few years. Gross profit is a required income statement account that reflects total revenue of BioNTech SE minus its cost of goods sold. It is profit before BioNTech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. BioNTech's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 16.07 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

BioNTech Gross Profit Regression Statistics

	Arithmetic Mean	2,352,333,937
	Coefficient Of Variation	210.26
	Mean Deviation	3,537,044,174
	Median	(33,216,000)
	Standard Deviation	4,946,061,451
	Sample Variance	24463523.9T
	Range	15.3B
	R-Value	0.57
	Mean Square Error	17699512.9T
	R-Squared	0.33
	Significance	0.03
	Slope	633,571,698
	Total Sum of Squares	342489334.3T

BioNTech Gross Profit History

	2024	4.8 B
	2023	3.2 B
	2022	12.8 B
	2021	15.1 B
	2020	-222 M
	2019	-135.2 M
	2018	-29.2 M

Other Fundumenentals of BioNTech SE

Gross Profit Margin

BioNTech Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Long Term Investments	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	0.62	-0.93	0.99	0.94	0.69	0.82	0.76	0.86	0.75	1.0	0.67	0.81	0.67	1.0	1.0	0.86
Total Stockholder Equity	1.0		0.62	-0.95	1.0	0.95	0.65	0.83	0.78	0.84	0.78	0.99	0.63	0.83	0.66	1.0	1.0	0.85
Current Deferred Revenue	0.62	0.62		-0.53	0.6	0.8	0.27	0.79	0.74	0.49	0.72	0.59	0.46	0.78	0.72	0.62	0.6	0.85
Net Debt	-0.93	-0.95	-0.53		-0.95	-0.88	-0.44	-0.78	-0.72	-0.69	-0.74	-0.92	-0.37	-0.78	-0.58	-0.94	-0.94	-0.78
Retained Earnings	0.99	1.0	0.6	-0.95		0.95	0.61	0.85	0.8	0.81	0.8	0.99	0.59	0.84	0.62	1.0	0.99	0.83
Accounts Payable	0.94	0.95	0.8	-0.88	0.95		0.5	0.94	0.9	0.73	0.89	0.92	0.59	0.94	0.71	0.95	0.93	0.89
Net Receivables	0.69	0.65	0.27	-0.44	0.61	0.5		0.25	0.17	0.92	0.15	0.72	0.92	0.25	0.52	0.65	0.68	0.55
Good Will	0.82	0.83	0.79	-0.78	0.85	0.94	0.25		0.99	0.51	0.99	0.78	0.41	0.99	0.54	0.83	0.8	0.8
Short Term Investments	0.76	0.78	0.74	-0.72	0.8	0.9	0.17	0.99		0.43	1.0	0.71	0.35	0.99	0.46	0.77	0.74	0.73
Total Liab	0.86	0.84	0.49	-0.69	0.81	0.73	0.92	0.51	0.43		0.41	0.89	0.9	0.51	0.67	0.84	0.86	0.77
Long Term Investments	0.75	0.78	0.72	-0.74	0.8	0.89	0.15	0.99	1.0	0.41		0.71	0.31	0.99	0.45	0.77	0.74	0.71
Total Current Assets	1.0	0.99	0.59	-0.92	0.99	0.92	0.72	0.78	0.71	0.89	0.71		0.69	0.77	0.66	0.99	1.0	0.84
Short Term Debt	0.67	0.63	0.46	-0.37	0.59	0.59	0.92	0.41	0.35	0.9	0.31	0.69		0.41	0.6	0.63	0.65	0.64
Intangible Assets	0.81	0.83	0.78	-0.78	0.84	0.94	0.25	0.99	0.99	0.51	0.99	0.77	0.41		0.59	0.83	0.8	0.8
Common Stock	0.67	0.66	0.72	-0.58	0.62	0.71	0.52	0.54	0.46	0.67	0.45	0.66	0.6	0.59		0.66	0.66	0.84
Net Invested Capital	1.0	1.0	0.62	-0.94	1.0	0.95	0.65	0.83	0.77	0.84	0.77	0.99	0.63	0.83	0.66		1.0	0.86
Net Working Capital	1.0	1.0	0.6	-0.94	0.99	0.93	0.68	0.8	0.74	0.86	0.74	1.0	0.65	0.8	0.66	1.0		0.85
Capital Stock	0.86	0.85	0.85	-0.78	0.83	0.89	0.55	0.8	0.73	0.77	0.71	0.84	0.64	0.8	0.84	0.86	0.85

Click cells to compare fundamentals

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	3.2 B	4.8 B
Gross Profit Margin	0.84	0.89

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC